Chronic Disease Working Group CCSS Investigator Meeting 2017

Kevin Oeffinger







Chronic Disease Working Group Core

<u>Individual</u>

Kevin Oeffinger Eric Chow (co-chair) Charles (Chuck) Sklar (Ex-officio) Melissa Hudson Louis (Sandy) Constine Todd Gibson **Christopher Weldon Daniel Mulrooney Emily Tonorezos** Sogol (Goli) Mostoufi-Moab Elizabeth (Beth) Wells Rebecca Howell Kayla Stratton Wendy Leisenring

Expertise


Primary care Pediatric oncology Pediatric endocrinology Pediatric oncology Radiation oncology Epidemiology, CCSS Project Dir Surgery Pediatric oncology Primary care Pediatric endocrinology / oncology Pediatric neuro-oncology Radiation physics / dosimetry Biostatistician Lead biostatistician

Chronic condition categories	Therapeutic exposures	Cancer groups
Vision	Radiation	ALL
Hearing	Body areas	AML
Speech	Dosimetry	Other leukemia
Endocrine	Volume	Medulloblastoma
Respiratory	Chemotherapy	Other CNS
Cardiovascular	Yes/no	Hodgkin lymphoma
Gastrointestinal	Cumulative dose	NHL
Renal	CED	Neuroblastoma
Musculoskeletal	Dox-equivalent	Wilms tumor
Neurologic	Combinations	Soft tissue sarcoma
Other hematologic	Surgery	Osteosarcoma
Infection		Ewing sarcoma

Common Terminology Criteria for Adverse Events

- Original NEJM analysis: 114 conditions
- Aging / expansion cohort: significant increase in the number of conditions
- Universal need for standardized grading that is generalizable, transparent, and can be refined
- CTCAE task force: Sklar, Hudson, Nathan, Armstrong, Chow, Tonorezos, Mostoufi-Moab, Wells, Gibson, Smith, <u>Barnea</u>, <u>Stratton</u>, Leisenring

Master Matrix for Chronic Conditions – by Condition



Master Matrix for Chronic Conditions – Using ICD codes

	А	В	С	DE	F	
1	Organ system	Variable #	Chronic Condition	Grade ICD 9/10 code with label	ICD code	
336	Cardiovascular	14	Heart Attack	00.66 Percutaneous transluminal coronary angioplasty [PTCA] or coronary atherectomy Balloon angioplasty of coronary artery Coronary atherectomy Percutaneous coronary angioplasty NOS PTCA NOS Code also any: injection or infusion of thrombolytic agent (99.10) insertion of coronary artery stent(s) (36.06-36.07) intracoronary artery thrombolytic infusion (36.04) number of vascular stents inserted (00.45-00.48) number of vessels treated (00.40- 4 00.43) procedure on vessel bifurcation (00.44) SuperSaturated oxygen therapy (00.49)		
337	Cardiovascular	14	Heart Attack	ry angioplasty NOS Code also any: f vessels treated (00.40-00.43) pen angioplasty (36.03) that by coronary atherectomy (00.66) t otherwise specified Direct	36.09	
				vein graft coronary with catheter		
338	Cardiovascular		Heart Attack	CD9-10 rt revascularization NOS	36.1	
339	Cardiovascular		Heart Attack		410	
340	Cardiovascular		Heart Attack	codes included	410.8	
341	Cardiovascular		Heart Attack		410.9	
342	Cardiovascular		Heart Attack	sode of care unspecified	410.9	
343	Cardiovascular		Heart Attack		411	
344	Cardiovascular		Heart Attack		411.1	
345	Cardiovascular		Heart Attack		411.8 411.81	
346	Cardiovascular		Heart Attack			
347	Cardiovascular		Heart Attack	3 412. Old myocardial infarction		
348	Cardiovascular		Heart Attack	3 413.1		
349	Cardiovascular		Heart Attack	3 413.9 Other and unspecified angina pectoris		
350	Cardiovascular		Heart Attack	5 414.: oth chr ischemic hrt dis		
351	Cardiovascular		Heart Attack	3 414.0: coronary atherosclerosis		
352	Cardiovascular		Heart Attack	5 414.0: coronary atherosclerosis 3 414.00 Coronary atherosclerosis of unspecified type of vessel, native or graft 4		
353	Cardiovascular		Heart Attack			
354	Cardiovascular	14	Heart Attack	4 414.05 Coronary atherosclerosis of unspecified bypass graft 4		

Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study

Nickhill Bhakta, Qi Liu, Frederick Yeo, Malek Baassiri, Matthew J Ehrhardt, Deo K Srivastava, Monika L Metzger, Matthew J Krasin, Kirsten K Ness, Melissa M Hudson, Yutaka Yasui, Leslie L Robison

Summary

Background The magnitude of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma is not known. Using medically ascertained data, we applied the cumulative burden metric to compare chronic cardiovascular health conditions in survivors of Hodgkin's lymphoma and general population controls.

Lancet Oncol 2016; 17: 1325-34 Published Online July 25, 2016 http://dx.doi.org/10.1016/ \$1470-2045(16)30215-7

Conditions categorized as:

- Chronic, non-recurrent conditions (eg, hypercholesterolemia)
- Single, recurrent conditions (eg, thrombus)
- Chronic, recurrent (cardiomyopathy, surgical intervention)

Largely based upon in-person, <u>detailed examination</u> with the opportunity to clarify on <u>sequence</u> of events.

Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study


Nickhill Bhakta, Qi Liu, Frederick Yeo, Malek Baassiri, Matthew J Ehrhardt, Deo K Srivastava, Monika L Metzger, Matthew J Krasin, Kirsten K Ness, Melissa M Hudson, Yutaka Yasui, Leslie L Robison

Summary

Background The magnitude of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma is not known. Using medically ascertained data, we applied the cumulative burden metric to compare chronic cardiovascular health conditions in survivors of Hodgkin's lymphoma and general population controls.

Lancet Oncol 2016; 17: 1325-34 Published Online July 25, 2016

http://dx.doi.org/10.1016/ 51470-2045(16)30215-7



Cumulative Burden in CCSS


- Limitations:
 - Self-report vs in-person examination
 - Unable to distinguish between two separate events (eg, two different episodes of thrombus)
- Adaptations:
 - Count each individual type of cancer
 - No adjustment with other chronic conditions
 - Caveats

Selected Publications 2015-2016

- 1. Overall estimates of chronic conditions and how they influence health status
- 2. By condition or outcome
- 3. By organ system
- 4. By (special) cancer types
- 5. Chronic conditions as a consequence of a benign neoplasm
- 6. How chronic conditions influence psychosocial issues
- 7. Chronic conditions and utility-based, health-related quality of life

Effect of Temporal Changes in Therapeutic Exposure on Self-reported Health Status in Childhood Cancer Survivors


Kirsten K. Ness, PhD*; Melissa M. Hudson, MD*; Kendra E. Jones, MS; Wendy Leisenring, ScD; Yutaka Yasui, PhD; Yan Chen, MS; Marilyn Stovall, PhD; Todd M. Gibson, PhD; Daniel M. Green, MD; Joseph P. Neglia, MD; Tara O. Henderson, MD; Jacqueline Casillas, MD; Jennifer S. Ford, PhD; Karen E. Effinger, MD, MS; Kevin R. Krull, PhD; Gregory T. Armstrong, MD, MSCE; Leslie L. Robison, PhD; Kevin C. Oeffinger, MD†; and Paul C. Nathan, MD†



Pregnancy after <u>chemotherapy</u> in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort



Lancet Oncol 2016; 17: 567–76




Recurrent stroke in childhood cancer survivors Neurology 85 September 22, 2015

Heather J. Fullerton, MD, MAS Kayla Stratton, MS Sabine Mueller, MD, PhD Wendy W. Leisenring,



Cumulative incidence of recurrent stroke in childhood cancer survivors



Recurrent stroke in childhood cancer survivors Neurology 85 September 22, 2015

Heather J. Fullerton, MD, MAS Kayla Stratton, MS Sabine Mueller, MD, PhD Wendy W. Leisenring,

Characteristics	Recurrence (n = 52), n (%)	No recurrence (n = 161), n (%)	HR (95% CI)	p Value
First stroke symptom duration >24 h	40 (77)	96 (60)	1.9 (1.0-3.6)	0.057
Presentation with hemiparesis	30 (58)	111 (69)	0.6 (0.3-1.0)	0.064
Stroke risk factors ^b				
Narrowing of blood vessels to brain	4 (8)	9 (6)	1.3 (0.5-3.6)	0.62
Moyamoya	5 (10)	5 (3)	2.6 (1.0-6.5)	0.044
Hypertension	24 (46)	48 (30)	3.3 (1.9-5.7)	<0.0001
Diabetes mellitus	5 (10)	12 (7)	2.3 (0.9-5.7)	0.08
Smoking (ever)	7 (13)	43 (27)	0.7 (0.3-1.6)	0.45

SEXUAL MEDICINE

ONCOLOGY

Erectile Dysfunction in Male Survivors of Childhood Cancer—A Report From the Childhood Cancer Survivor Study



Chad W. M. Ritenour, MD,¹ Kristy D. Seidel, MS,² Wendy Leisenring, ScD,^{2,3} Ann C. Mertens, PhD,^{4,5} Karen Wasilewski-Masker, MD,^{4,5} Margarett Shnorhavorian, MD,⁶ Charles A. Sklar, MD,⁷ John A. Whitton, MS,² Marilyn Stovall, PhD,⁸ Louis S. Constine, MD,⁹ Gregory T. Armstrong, MD, MSCE,¹⁰ Leslie L. Robison, PhD,¹⁰ and Lillian R. Meacham, MD^{4,5}

Outcome measurement	Frequency (% yes)	Unadjusted relative risk (95% CI)	Adjusted relative risk (95% CI)*
ED			
Survivors	143/1,166 (12)	2.90 (1.50–5.60)	2.63 (1.40-4.97)
Siblings	9/213 (4)	1.00 (referent)	1.00 (referent)
Self-reported treatment for ED			
Survivors	88/1,474 (6)	2.59 (1.14–5.86)	2.73 (1.26-5.94)
Siblings	6/260 (2)	1.00 (referent)	1.00 (referent)

Table 3. Multivariable comparison summary of survivors and siblings for ED and treatment of ED

ED = erectile dysfunction; IIEF-EF = International Index of Erectile Function erectile function domain.


*Adjusted for age at time of completing the Male Health Questionnaire, general health level, physical activity, at least grade 3 cardiac condition, hypertension requiring medication, diabetes, depression and other major psychiatric illness, prostate disease, and current use of exogenous testosterone.

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT


Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study

Sogol Mostoufi-Moab, Kristy Seidel, Wendy M. Leisenring, Gregory T. Armstrong, Kevin C. Oeffinger, Marilyn Stovall, Lillian R. Meacham, Daniel M. Green, Rita Weathers, Jill P. Ginsberg, Leslie L. Robison, and Charles A. Sklar




Risk and Impact of Pulmonary Complications in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study Cancer December 1, 2016

Andrew C. Dietz, MD, MSCR¹; Yan Chen, MMath²; Yutaka Yasui, PhD³; Kirsten K. Ness, PhD³; James S. Hagood, MD⁴; Eric J. Chow, MD, MPH⁵; Marilyn Stovall, PhD⁶; Joseph P. Neglia, MD, MPH⁷; Kevin C. Oeffinger, MD⁸; Ann C. Mertens, PhD⁹; Leslie L. Robison, PhD³; Gregory T. Armstrong, MD, MSCE³; and Daniel A. Mulrooney, MD, MS³



Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study

Allison A. King, Kristy Seidel, Chongzhi Di, Wendy M. Leisenring, Stephanie Mabry Perkins, Kevin R. Krull, Charles A. Sklar, Daniel M. Green, Gregory T. Armstrong, Lonnie K. Zeltzer, Elizabeth Wells, Marilyn Stovall, Nicole J. Ullrich, Kevin C. Oeffinger, Leslie L. Robison, and Roger J. Packer




JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

Morbidity and Mortality Associated With Meningioma After Cranial Radiotherapy: A Report From the Childhood Cancer Survivor Study


Daniel C. Bowers, Chaya S. Moskowitz, Joanne F. Chou, Claire M. Mazewski, Joseph P. Neglia, Gregory T. Armstrong, Wendy M. Leisenring, Leslie L. Robison, and Kevin C. Oeffinger



Impact of Chronic Disease on Emotional Distress in Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study

Stefanie C. Vuotto, PhD¹; Kevin R. Krull, PhD¹; Chenghong Li, PhD²; Kevin C. Oeffinger, MD³; Daniel M. Green, MD¹; Sunita K. Patel, PhD⁴; Deokumar Srivastava, PhD²; Marilyn Stovall, PhD⁵; Kirsten K. Ness, PhD¹; Gregory T. Armstrong, MD, MSCE¹; Leslie L. Robison, PhD¹; and Tara M. Brinkman, PhD¹

Cancer February 1, 2017




VOLUME 33 · NUMBER 32 · NOVEMBER 10 2015

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer

Elizabeth A.M. Feijen, Wendy M. Leisenring, Kayla L. Stratton, Kirsten K. Ness, Helena J.H. van der Pal, Huib N. Caron, Gregory T. Armstrong, Daniel M. Green, Melissa M. Hudson, Kevin C. Oeffinger, Leslie L. Robison, Marilyn Stovall, Leontien C.M. Kremer, and Eric J. Chow





JNCI J Natl Cancer Inst (2016) 108(9): djw046

doi: 10.1093/jnci/djw046 First published online April 21, 2016 Brief Communication

BRIEF COMMUNICATION

Chronic Conditions and Utility-Based Health-Related Quality of Life in Adult Childhood Cancer Survivors

Jennifer M. Yeh, Janel Hanmer, Zachary J. Ward, Wendy M. Leisenring, Gregory T. Armstrong, Melissa M. Hudson, Marilyn Stovall, Leslie L. Robison, Kevin C. Oeffinger, Lisa Diller




Table 2. SF-6D utility scores for CCSS survivors by number and severity of chronic conditions*

What are some of our current ongoing studies and concepts?



• Sogol (Goli) Mostoufi-Moab (2013)

Overall risk of Chronic <u>Endocrine</u> Disorders in Adult Survivors of Childhood Cancer

• Danielle Novetsky Friedman (2015)

Impact of radiation dose to the <u>pancreas</u> on subsequent risk of <u>diabetes</u> mellitus

- Adam Esbenshade (2015)
 Using the <u>Cumulative Illness Rating Scale</u> to characterize the burden of chronic conditions
- Miranda Fidler (2015)

Comparison of risks for mortality and subsequent cancers in the CCSS and the <u>BCCSS</u>

EQĪAL

Emily Tonorezos R01CA187397

- 24-month RCT comparing the effect of a weband telephone-based weight loss intervention (led by *Healthways at Hopkins*) to general information about weight loss and healthy living (control).
- Calculate the effect of the diet and physical activity intervention, compared to self- directed weight loss, on three key <u>metabolic biomarkers</u>:
 - a. Fasting insulin
 - b. Leptin:adiponectin ratio
 - c. Small, dense LDL



Communicating Health Information & Improving Coordination with Primary Care

Eric Chow R01CA204378

- 1. Determine the prevalence of underdiagnosis and undertreatment of hypertension, dyslipidemia, and diabetes in CCSS participants at high risk of future heart disease.
- 2. Among those underdiagnosed / undertreated, conduct an RCT to test the effect of a remotely delivered SCP & self-management intervention on rates of undertreatment after 1-year.
- 3. Determine barriers among survivors & PCPs towards survivorship care that contribute to undertreatment of common modifiable CV risk factors.



Communicating Health Information & Improving Coordination with Primary Care

Eric Chow R01CA204378

- 1. Determine the prevalence of underdiagnosis and undertreatment of <u>hypertension</u>, <u>dyslipidemia</u>, <u>and diabetes</u> in CCSS participants at high risk of future heart disease.
- 2. Among those underdiagnosed / undertreated, conduct an RCT to test the effect of a remotely delivered SCP & self-management intervention on rates of undertreatment after 1-year.
- 3. Determine barriers among survivors & PCPs towards survivorship care that contribute to undertreatment of common modifiable CV risk factors.

ACS Research Scholar Grant Jennifer Yeh

Improving Cancer Screening Guidelines for Survivors of Childhood Cancer

Specific Aims

- 1. Develop a Childhood Cancer Survivorship Simulation Model
- 2. Project the lifelong <u>magnitude</u> and heterogeneity in disease <u>burden</u> associated with <u>late-effects</u> among childhood cancer survivors
- 3. Assess the comparative effectiveness of secondary cancer screening strategies to improve long-term outcomes among at-risk survivors

Contemporary Risk-Adapted Therapy for Hodgkin Lymphoma: What are the Trade-Offs?

- Estimate all-cause and cause-specific <u>mortality</u> for 5+ year survivors of Hodgkin lymphoma diagnosed 1970-1999 and compare by era of therapy and by major treatment groupings.
- 2. Determine the incidence of <u>chronic health conditions</u> and compare by era of therapy and by major treatment groupings.
- Estimate risks of chronic health conditions (any condition, grade 3-5 conditions, multiple grade 3-5 conditions) with <u>contemporary</u> HL therapy - use data from CCSS to create groups with similar exposures to two contemporary Children's Oncology Group (COG) protocols – AHOD 0031 and AHOD 0431.
- Merge data with Dutch HL cohort to look more closely at <u>treatment exposures</u> and <u>trade-offs</u> (combined data almost 5,500 HL survivors).



- Gibson TM, Mostoufi-Moab S, Stratton K, Barnea D, Chow EJ, Donaldson SS, Howell R, Hudson MM, Leisenring WM, Mahajan A, Nathan PC, Ness KK, Sklar CA, Tonorezos ES, Weldon CB, Wells EM, Yasui Y, Armstrong GT, Robison LL, Oeffinger KC. <u>Temporal trends in</u> <u>chronic disease among survivors of childhood cancer diagnosed across</u> <u>three decades</u>: a report from the Childhood Cancer Survivor Study (CCSS). American Society of Clinical Oncology; 15th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer.
- Weil B, Madenci A, Liu Q, Gibson T, Yasui Y, Neglia J, Leisenring W, Howell R, Tonorezos E, Friedman D, Tinkle C, Diller L, Armstrong GT, Oeffinger K, Weldon C. <u>Infection related late mortality in survivors of</u> <u>childhood cancer with asplenia or radiation-induced hyposplenism</u>: a report from the Childhood Cancer Survivor Study. 15th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer.



- Bates JE, Liu Q, Yasui Y, Howell RM, Mulrooney DA, Dhakal S, Leisenring WM, Indelicato DJ, Gibson TM, Armstrong GT, Oeffinger KC, Constine LS. <u>Age-associated vulnerability to treatment-related late</u> <u>cardiotoxicity</u>: a report from the Childhood Cancer Survivor Study (CCSS). American Society of Clinical Oncology.
- Bates JE, Howell RM, Liu Q, Yasui Y, Mulrooney DA, Dhakal S, Leisenring WM, Indelicato DJ, Gibson TM, Armstrong GT, Oeffinger KC, Constine LS. <u>Volumetric dose-effect analysis of late cardiotoxicity</u>: a report from the Childhood Cancer Survivor Study (CCSS). American Society for Radiation Oncology Annual Meeting
- Salloum R, Chen Y, Yasui Y, Packer R, Leisenring W, Wells E, King A, Howell R, Gibson TM, Krull KR, Robison LL, Oeffinger KC, Fouladi M, Armstrong GT. <u>Temporal trends in late-onset morbidity and mortality</u> <u>after medulloblastoma diagnosed across three decades</u>: a report from the Childhood Cancer Survivor Study. American Society of Clinical Oncology.



- Dietz AC, Seidel K, Leisenring WM, Mulrooney DA, Tersak JM, Glick RD, Burnweit CA, Green DM, Diller L, Oeffinger KC, Smith SA, Howell RM, Stovall M, Robison LL, Armstrong GT, Termuhlen AM. <u>Solid organ</u> <u>transplant after treatment for childhood cancer</u>: a report from the Childhood Cancer Survivor Study. 15th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer.
- Tonorezos ES, Meacham L, Chou JF, Moskowitz CS, Leisenring WM, Freidman D, Sklar CA, Dilley KJ, Hudson M, Mertens A, Armstrong GT, Robison LL, Oeffinger KC. <u>Risk of increased mortality in underweight</u> <u>survivors</u>: a report from the Childhood Cancer Survivor Study. 15th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer.



 Brooke RJ, Chemaitilly W, Wilson CL, Krasin MJ, Li Z, Im C, Morton LM, Wu G, Wang Z, Chen W, Howell RM, Armstrong GT, Bhatia S, Chanock SJ, Zhang J, Green DM, Sklar CA, Hudson MM, Robison LL, Yasui Y. <u>A high-risk genetic profile for premature menopause (PM) in</u> <u>childhood cancer survivors (CCS) exposed to gonadotoxic therapy</u>: a report from the St. Jude Lifetime Cohort (SJLIFE) and Childhood Cancer Survivor Study (CCSS). American Society of Clinical Oncology; 15th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer.



- Madenci AL, Weil BR, Liu Q, Gibson TM, Yasui Y, Leisenring WM, Howell RM, Tinkle C, Nekhlyudov L, Diller L, Armstrong GT, Oeffinger KC, Weldon CB. Long-term incidence of venous thromboembolism (VTE) among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. American Society of Clinical Oncology; 15th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer.
- Fejien EA, Leisenring WM, Stratton KL, Ness KK, Van der Pal HJH, van Dalen EC, Armstrong GT, Aune GJ, Green DM, Hudson MM, Loonen J, Oeffinger KC, Robison LL, Yasui Y, Kremer LC, Chow EJ.
 <u>Equivalence ratios for late cardiomyopathy after doxorubicin and other</u> <u>anthracyclines/anthraquinones</u>. 15th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer.



- Lupo PJ, Brown AL, Kamdar KY, Belmont JW, Armstrong GT, Leisenring WM, Oeffinger KC, Okcu F, Robison LL, Scheurer ME, Yasui Y, Bhatia S. <u>DNA methylation and obesity in survivors of pediatric Acute</u> <u>Lymphoblastic Leukemia (ALL)</u>: a report from the Childhood Cancer Survivor Study (CCSS). 15th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer.
- Mueller S, Chen Y, Yasui Y, Fullerton HJ, Howell R, Oeffinger K, Robison LL, Armstrong GT, Krull KR. <u>Impact of stroke and stroke</u> recurrence on late mortality as well as psychological and <u>socioeconomic outcomes in childhood cancer survivors</u>. Pediatric Neuro-Oncology Basic and Translational Research Conference.

List of current Applications of Intent and Concept Proposals - pages 45-51 of the CCSS booklet

Looking to the Future



- Increased use of Cisplatin (739 original cohort + 1,353 in expansion = 2,092 overall)
 - Hearing, renal function, cardiac disease
- Increased use of Ifosfamide (190 original cohort + 978 in expansion = 1,168 overall)
 - Renal function
- Almost 12,000 survivors exposed to anthracyclines overall
 - Heart rate variability, autonomic dysfunction



mHealth and Chronic Disease

- Home measurement of:
 - Blood pressure
 - Heart rate, HR variability, EKH
 - Glucose, A1C, lipids
 - Pulmonary function tests
- Subcontract and combine with Examination Management Services, Inc (EMSI), used in pilot home sample, EQUAL, and CHIIP
 - Urine testing (electrolytes, creatinine, etc)
 - Other fasting labs
 - Height and weight



Key chronic conditions with potential interaction between genetic factors, lifestyle behaviors and treatment exposures:

- Key adverse outcomes
- Hearing
- Valvular heart disease (valve replacement)
- Pulmonary fibrosis
- Diabetes



R21 or medium-sized grants to support case-control study

- Stroke radiation, hypertension, genetic factors
- Coronary artery disease with volumetric radiation exposure by arterial distribution to model for contemporary radiation therapy
- Leading to R01-supported intervention trials
- Statin therapy (risk communication)
- Hypertension management (via mHealth approach)

Thanks (to the many, many investigators working on chronic disease projects)

Questions?

kevin.oeffinger@duke.edu